Drug & intervention
osimertinib
RxCUI 1721560
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
40 shownOsimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerNCT07738172 · 2026-09-08
RECRUITINGA Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)NCT07640789 · 2026-08-28
RECRUITINGLurbinectedin With Osimertinib in Transformed Small Cell Lung CancerNCT07153055 · 2026-08-01
RECRUITINGA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)NCT07642024 · 2026-07-24
RECRUITINGA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)NCT07622186 · 2026-07-15
RECRUITINGA Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerNCT07669779 · 2026-07-10
RECRUITINGA Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerNCT07535437 · 2026-04-09
RECRUITINGOsimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm StudyNCT07295821 · 2026-04-01
RECRUITINGPhase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT07329322 · 2026-03-30
RECRUITINGTelisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung CancerNCT07323641 · 2026-02-19
RECRUITINGStudy of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerNCT07315113 · 2025-12-18
RECRUITINGA ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyNCT07375316 · 2025-12-15
RECRUITINGA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerNCT07155187 · 2025-12-10
RECRUITINGStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)NCT07079475 · 2025-07-30
RECRUITINGA Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)NCT06838273 · 2025-02-24
RECRUITINGA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsNCT06618287 · 2025-02-04
RECRUITINGA Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the BrainNCT06741085 · 2024-12-13
RECRUITINGA Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsNCT06735391 · 2024-10-23
RECRUITINGA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814 · 2024-10-04
RECRUITINGVebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.NCT06574347 · 2024-08-07
RECRUITINGPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung CancerNCT06350097 · 2024-04-29
RECRUITINGIntra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung CancerNCT06304441 · 2024-04-18
RECRUITINGNeoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell CarcinomaNCT06383728 · 2024-04-01
RECRUITINGStudy of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerNCT05401110 · 2023-09-15
RECRUITINGA Study of DB-1310 in Advanced/Metastatic Solid TumorsNCT05785741 · 2023-08-17
RECRUITINGTY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesNCT05948813 · 2023-08-17
RECRUITINGTesting the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12
RECRUITINGComparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)NCT05642572 · 2023-05-05
RECRUITINGOsimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)NCT05686434 · 2022-10-14
RECRUITINGEGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyNCT06486142 · 2022-09-21
RECRUITINGPhase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)NCT05382728 · 2022-06-08
RECRUITINGOsimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerNCT04780568 · 2022-01-18
RECRUITINGAdditional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)NCT05281406 · 2021-11-12
RECRUITINGQuaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibNCT04486833 · 2021-09-03
RECRUITINGNeoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLCNCT05011487 · 2021-08-13
RECRUITINGMRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerNCT04762199 · 2021-02-24
RECRUITINGOsimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28
RECRUITINGOsimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersNCT04410796 · 2020-05-28
RECRUITINGTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationNCT04322890 · 2020-04-16
RECRUITINGTesting Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNCT03191149 · 2018-04-25
RECRUITINGConditions being studied
Non-Small Cell Lung Cancer40Non Small Cell Lung Cancer17Lung Cancer15Stage IV Lung Cancer AJCC v814Carcinoma, Non-Small-Cell Lung12EGFR Gene Mutation12NSCLC11Metastatic Lung Non-Small Cell Carcinoma9Stage IVA Lung Cancer AJCC v88Stage IVB Lung Cancer AJCC v88EGFR Activating Mutation7Recurrent Lung Non-Small Cell Carcinoma7Stage IIIB Lung Cancer AJCC v86Advanced Lung Non-Small Cell Carcinoma5EGFR T790M5Carcinoma4Leptomeningeal Metastasis4Metastatic Non-Small Cell Lung Cancer4Non-Small Cell Lung Cancer (NSCLC)4Stage III Lung Cancer AJCC v84
Research locations
Leading sponsors
AstraZeneca20National Cancer Institute (NCI)9Memorial Sloan Kettering Cancer Center7Guangdong Association of Clinical Trials5Daping Hospital and the Research Institute of Surgery of the Third Military Medical University4Sichuan Baili Pharmaceutical Co., Ltd.4AbbVie3Dana-Farber Cancer Institute3M.D. Anderson Cancer Center3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.3Blueprint Medicines Corporation2Bristol-Myers Squibb2City of Hope Medical Center2CSPC Megalith Biopharmaceutical Co.,Ltd.2Daiichi Sankyo2
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.